and had a minimum follow-up of 6 months. After inducing an artificial erection intraoperatively, PP was performed through a longitudinal penile incision. We updated our surgical technique in 2016 by (a) using supplemental intracorporal saline injections if the initial erection response to prostaglandin E1 injection was inadequate, and (b) placement of plication sutures beginning proximally and progressing distally as needed. Patients were stratified into two groups-prior technique and current technique. The primary outcome assessed was revision rate. Secondary outcomes included pre and post-operative curvature and number of sutures placed intraoperatively.
INTRODUCTION AND OBJECTIVES: Peyronie's disease (PD)
is an acquired condition typically characterized by plaque formation and dorsal/lateral penile curvature. Atypical PD is a term used to describe less common PD presentations such as ventral curvature, multiplanar curvature, penile indentation and hourglass deformity. We sought to assess the outcomes of patients with atypical PD presenting to a men's health clinic.
METHODS: We conducted a retrospective review of charts of men who presented to the clinic with atypical PD between October 2016 and October 2018. Patients were included if they were considered to be in the stable phase of the disease and had completed a penile duplex Doppler ultrasound (PDDU) prior to any intervention. Gathered data included patient demographics and treatment details, outcomes and complications. Offered treatments included intralesional injection of Collagenase Clostridium Histolyticum (CCH), tunical plication (TP), partial excision and grafting (PEG) and insertion of inflatable penile prosthesis (IPP).
RESULTS: During this period, 74 men with stable PD underwent PDDU, of which 42 (56.8%) were found to have atypical PD. Of these, 32 (76.2%) had penile indentation, 14 (33.3%) had a multiplanar curvature, 10 (23.8%) had a ventral curvature, and 10 (23.8%) had an hourglass deformity. Overall, 31/42 (73.8%) patients opted for treatment: 22 (70.9%) CCH injections, 4 (12.9%) TP, 4 (12.9%) IPP, and 1 (3.3%) PEG. The remaining 11 patients did not pursue treatment, mostly due to insurance coverage issues. Patients with ventral curvature underwent CCH (62.5%), PEG, TP and IPP (12.5% each); multiplanar curvature underwent CCH (77.8%) and TP (22.2%); penile indentation CCH (72.0%), TP, IPP (12.0% each) and PEG (4%); hourglass deformity CCH (77.8%) and PEG (22.2%). Patients who underwent surgery had a mean improvement in curvature of 45.0 AE 10.8 degrees (85.5 AE 17.5%); 100% with significant (! 20%) change in curvature. Patients who underwent CCH injections had a mean improvement in curvature of 13.5 AE 5.7 degrees (33.1 AE 10.4%); 90% with ! 20% change in curvature. The mean number of CCH injections used was 6.4 AE 3. There was 1 penile fracture in the CCH group which required surgical repair. There were no complications in the surgery groups.
CONCLUSIONS: Patients with atypical PD represent a significant proportion of men with PD. Surgery represents an excellent option in this group. Outcomes with CCH in patients with atypical PD are comparable to those reported in the IMPRESS trials. . However, existing PTT devices require daily utilization for !5 hours and data regarding penile curvature and length improvements are inconsistent and of unclear clinical benefit. Given these limitations, a novel PTT device, RestoreX, was developed specifically as a primary or adjunctive therapy for PD. Here, we sought to assess the safety and efficacy of the RestoreX PTT device in men with PD.
METHODS: A randomized, controlled trial (NCT03389854) is ongoing to evaluate the impact of PTT with RestoreX in 120 men with PD. Men are randomized to one of four groupings: no therapy (control) or treatment with Restorex for 30 minutes 1x, 2x, or 3x daily for 3 months. All men then enter an open label phase for an additional 3 months. Inclusion criteria are no current or recent PD therapies and !30 degrees curvature. The primary outcome is safety, and secondary outcomes include penile length, curvature, and subjective responses to standardized (IIEF, PDQ) and non-standardized questionnaires. Assessments are obtained at baseline and 3 and 6 months after starting therapy.
RESULTS: A total of 117 men have been enrolled to date, with 3-month data available on 85 patients (control, n[19, PTT, n[66) . Baseline clinicopathologic characteristics include a mean age of 58.4 (SD 7.8) years, mean PD duration 45.0 (42.0) months, mean primary curvature 45.7 (11.7) degrees, and mean stretched penile to coronal length of 11.5 (1.4) cm, all non-significant between PTT and controls. After 3 months of treatment, PTT significantly improved penile length (þ1.4 cm [þ9.9%] vs þ0.3 cm [2.1%], p<0.01), and primary penile curvature (-9 degrees [-18 .9%] vs -1.0 degrees [-2.4%], p<0.01) compared to controls. Results from the PD Questionnaire demonstrated significant improvements in the psychological/physical domain (PTT -2.6 vs -0.5, p[0.01). Of those who could not penetrate at baseline, 38% reported restored ability to penetrate (vs 0%, p<0.01), and 19% indicated that therapy negated a need for surgery. Adverse events with PTT were all mild and resolved within 5 minutes of completing therapy: mild discomfort (44%), erythema (39%), and sensory changes (15%).
CONCLUSIONS: Based on preliminary results, in a cohort of PD men, PTT with RestoreX for 30-90 minutes daily resulted in statistically significant improvements in penile length and curvature at 3 months compared to controls with no significant adverse events.
Source of Funding: PathRight Medical provided the devices to patients involved in the study free of charge. All other funding was internal.
